Springhood Child Health Ventures

Springhood Child Health Ventures is a venture capital investor that describes itself as the first focused broadly on children's health. It backs young companies working to significantly improve health outcomes for children. John Parker founded the firm to address the funding gap in child health innovation. Its portfolio includes clinical decision support for the discharge dilemma, a effort to cut the rare disease diagnostic journey from 7 years to 3 months, new small molecule cancer therapeutics starting with DIPG, and an intravenous treatment for dystrophic epidermis bullosa.